Biopharmaceutical Company
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include:  HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities S. Con. Res 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; pharmaceutical track and trace legislation (HR 1919 -- Safeguarding America's Pharmaceutical Act of 2013)
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
SLC HEALTH STRATEGIES, LLC
9710 Traville Gateway Drive, Number 157, Rockville, MD, 20850, US
SHARON COHEN SHARON COHEN SHARON COHEN SHARON COHEN